Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)

NCT03721341 is registered in ClinicalTrials.gov with David Palma as lead sponsor.

NCT NCT03721341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03721341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)
Lead sponsor
David Palma
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 22, 2019
Completion date
January 31, 2029
Enrollment
204 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic tumors